Wealthspire Advisors (New York)’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.01M | Buy |
479,518
+81,144
| +20% | +$171K | 0.01% | 383 |
|
|
2025
Q1 | $486K | Hold |
398,374
| – | – | ﹤0.01% | 521 |
|
|
2024
Q4 | $514K | Hold |
398,374
| – | – | 0.01% | 506 |
|
|
2024
Q3 | $1.1M | Hold |
398,374
| – | – | 0.01% | 357 |
|
|
2024
Q2 | $900K | Hold |
398,374
| – | – | 0.01% | 328 |
|
|
2024
Q1 | $952K | Buy |
398,374
+214,512
| +117% | +$513K | 0.01% | 325 |
|
|
2023
Q4 | $305K | Hold |
183,862
| – | – | ﹤0.01% | 519 |
|
|
2023
Q3 | $353K | Hold |
183,862
| – | – | 0.01% | 458 |
|
|
2023
Q2 | $265K | Hold |
183,862
| – | – | ﹤0.01% | 476 |
|
|
2023
Q1 | $386K | Buy |
+183,862
| New | +$386K | 0.01% | 395 |
|
|
2022
Q4 | – | Sell |
-17,355
| Closed | -$28K | – | 591 |
|
|
2022
Q3 | $28K | Hold |
17,355
| – | – | ﹤0.01% | 504 |
|
|
2022
Q2 | $23K | Hold |
17,355
| – | – | ﹤0.01% | 493 |
|
|
2022
Q1 | $28K | Buy |
17,355
+3,500
| +25% | +$5.65K | ﹤0.01% | 427 |
|
|
2021
Q4 | $29K | Hold |
13,855
| – | – | ﹤0.01% | 534 |
|
|
2021
Q3 | $54K | Hold |
13,855
| – | – | ﹤0.01% | 573 |
|
|
2021
Q2 | $44K | Hold |
13,855
| – | – | ﹤0.01% | 366 |
|
|
2021
Q1 | $30K | Hold |
13,855
| – | – | ﹤0.01% | 702 |
|
|
2020
Q4 | $31K | Hold |
13,855
| – | – | ﹤0.01% | 579 |
|
|
2020
Q3 | $37K | Hold |
13,855
| – | – | ﹤0.01% | 326 |
|
|
2020
Q2 | $42K | Hold |
13,855
| – | – | ﹤0.01% | 277 |
|
|
2020
Q1 | $27K | Hold |
13,855
| – | – | ﹤0.01% | 551 |
|
|
2019
Q4 | $40K | Hold |
13,855
| – | – | ﹤0.01% | 212 |
|
|
2019
Q3 | $51K | Buy |
+13,855
| New | +$51K | ﹤0.01% | 165 |
|